Charles River Laboratories Intl (CRL)

3 Mid-Cap Stocks That Fall Short

1 Unpopular Stock That Should Get More Attention and 2 We Question

Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2025 financial results and provide 2026 guidance on Wednesday, February 18 th , before...

Cell and Gene Therapy CDMO to bolster rare disease research at Gazi University Faculty of Medicine

NEW YORK and NEW ORLEANS , Jan. 20, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti , LLC ("KSF"), announces...

Charles River Laboratories is scheduled to report its fiscal fourth-quarter results shortly, with analysts forecasting a low–double-digit year-over-year decline in earnings.

– Signs Agreement to Acquire K.F. (Cambodia) Ltd. to Further Strengthen DSA Supply Chain; Transaction Expected to be Accretive to Non-GAAP Earnings Per Share by Approximately $0.25 in...

– Jim Foster, Chair, President & CEO, Announces Plans to Retire at the 2026 Annual Meeting of Shareholders in May 2026 After Distinguished 50-Year...

3 Overrated Stocks We Steer Clear Of

3 Low-Volatility Stocks We Think Twice About